Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP PNET5 medulloblastoma risk-adapted treatment study
2024-513724-42-00Phase 3Authorised
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label trial of carboplatin, vincristine, doxorubicin, cyclophosphamide, methotrexate and 3 more in medulloblastoma (4 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Event-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
carboplatinvincristinedoxorubicincyclophosphamidemethotrexate
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2024-513724-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513724-42-00.